For MZ SR:

For OZ Hope:

The meeting was launched by the Director General of the Department of Pharmacy and Drug Policy Dr. Adam Hlôška. He asked the deputy Civil association Hope (hereinafter referred to as "OZ") to present its requirements for adoption.

Mr Valčeková: She thanked those present for their acceptance and informed them that their OZ convened at 06.06.2012 press conference on the situation of initiating change The text of the indicative restrictions currently contained in the Association's view discriminatory. Since the last two negotiations at the Ministry of Health (hereinafter referred to as "the Ministry') led to a change in the indication restrictions, which are Patient view insufficient (e.g. assessment based on outdated Mc Donald criteria, non-equivalence of treatment criteria, treatment discontinuation if Patient 5 years with no symptoms, .....) the Ministry for the re-assessment of the wording of the indication restrictions so that it is patients allowed quality first line treatment. She appealed to representatives In order to adjust the indicative limits, the Ministry of Health should ensure that the patient is timely and consistent with the latest clinical trial results set to treat sclerosis multiplex.

She informed the audience that OZ is preparing a petition for a change in indication restriction and approval of free supportive treatment for walking disorders for patients diagnosed with multiple sclerosis. If the Ministry shows will address the issue discussed at the next meeting of the Categorisation Medicines Commissions, not yet submitted on the press conference,

MUDr. Hlôška: informed that the Categorisation Board for Medicinal Products is advisory body of the Minister, composed of 11 members (three for the Ministry, three for the professional companies and five health insurance companies) prepared by the Minister Health SR expert advice on decision-making regarding categorization medicinal products including changes in the characteristics of the reference groups of medicinal products to treat multiple sclerosis. He explained to the present categorisation process as well as the efforts of the Ministry to take into account the demands of the patient, and at the same time ensure effective cost of treatment. He stated that at the meeting of the Categorisation Commission on 06.06.2012 he would inform taking part in the meeting with the CC and their requests to change the indication restrictions.

Conclusion:

the indication limits are changed to be acceptable from the patient's point of view; and At the same time, to ensure effective cost-effectiveness of treatment, the requirement of OZ Hope

Minutes of the Categorisation Commission for Medicinal Products will be published on the website Ministry.

She wrote: Jell-O
Validated: - for OZ Hope Mr. Roller
Approval: MUDr. Adam Hlôška, v.r.